uniQure trial setback hits ClearPoint Neuro stock

Published on 10/06/2026 at 01:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 10.88 million in second-quarter 2026. For ClearPoint Neuro stock, guidance is USD 48.00-52.00 million and second-quarter loss USD 11.34 million.

CLPT, US18507C1036, Illustration mit AI erstellt.

ClearPoint Neuro (ISIN US18507C1036) was caught in a 24.00 percent share-price fall on September 29, 2026 after partner uniQure reported updated AMT-130 data, as Yahoo Finance reported. The result puts a major partner program and its possible future commercial revenue at the center of the ClearPoint Neuro stock story.

AMT-130 setback changes the risk picture

At 48 months, AMT-130 did not achieve statistical significance on a primary clinical measure, although uniQure reported dose-dependent slowing of disease progression, according to Yahoo Finance on September 29, 2026. ClearPoint supplies the MRI-guided navigation platform and SmartFlow cannula system used to deliver the therapy into the brain's striatum.

The commercial effect is conditional rather than immediate: future hardware and software revenue would depend on AMT-130 advancing through development, regulatory review and eventual market use. That makes clinical execution at uniQure an important external variable for ClearPoint's drug-delivery opportunity.

Second-quarter revenue missed expectations

ClearPoint reported USD 10.88 million of revenue in the second quarter of 2026, compared with a USD 12.73 million consensus estimate, while earnings per share showed a loss of USD 0.38 against an expected loss of USD 0.29, MarketBeat reported on September 6, 2026. The revenue shortfall was USD 1.85 million, or 14.53 percent below consensus, calculated from those two figures.

The quarter also showed the pressure on profitability: net loss reached USD 11.34 million, while operating cash flow was negative USD 7.02 million for the same period. Cash stood at USD 29.36 million on June 30, 2026, down from USD 35.59 million at the end of the first quarter.

Guidance remains a measurable test

ClearPoint's 2026 revenue outlook is USD 48.00 million to USD 52.00 million, according to the company's second-quarter materials summarized by Market Streets. The range implies a midpoint of USD 50.00 million, giving investors a concrete benchmark for the contribution from neurosurgery navigation, drug delivery and the acquired IRRAflow portfolio.

The company's investor-relations page identifies the latest reported period as the quarter ended June 30, 2026 and describes ClearPoint as a device, cell and gene therapy-enabling business serving healthcare and research centers across North America, Europe, Asia and South America.

Market value and listing context

ClearPoint Neuro had a market capitalization of USD 345.5 million on October 5, 2026. Its 52-week range was USD 8.27 to USD 30.10 on the same date, leaving the current valuation sensitive to clinical milestones as well as the company's revenue execution.